Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.
<h4>Background</h4>During the influenza pandemic of 2009/10, the whole-virion, Vero-cell-derived, inactivated, pandemic influenza A (H1N1) vaccine Celvapan® (Baxter) was used in Austria. Celvapan® is adjuvant-free and was the only such vaccine at that time in Europe. The objective of thi...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/738ef5870b3140ce8bcd14c42c4134ec |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:738ef5870b3140ce8bcd14c42c4134ec |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:738ef5870b3140ce8bcd14c42c4134ec2021-11-18T07:17:58ZImmunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.1932-620310.1371/journal.pone.0036773https://doaj.org/article/738ef5870b3140ce8bcd14c42c4134ec2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22629330/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>During the influenza pandemic of 2009/10, the whole-virion, Vero-cell-derived, inactivated, pandemic influenza A (H1N1) vaccine Celvapan® (Baxter) was used in Austria. Celvapan® is adjuvant-free and was the only such vaccine at that time in Europe. The objective of this observational, non-interventional, prospective single-center study was to evaluate the immunogenicity and tolerability of two intramuscular doses of this novel vaccine in HIV-positive individuals.<h4>Methods and findings</h4>A standard hemagglutination inhibition (HAI) assay was used for evaluation of the seroconversion rate and seroprotection against the pandemic H1N1 strain. In addition, H1N1-specific IgG antibodies were measured using a recently developed ELISA and compared with the HAI results. Tolerability of vaccination was evaluated up to one month after the second dose. A total of 79 HIV-infected adults with an indication for H1N1 vaccination were evaluated. At baseline, 55 of the 79 participants had an HAI titer ≥1:40 and two patients showed a positive IgG ELISA. The seroconversion rate was 31% after the first vaccination, increasing to 41% after the second; the corresponding seroprotection rates were 92% and 83% respectively. ELISA IgG levels were positive in 25% after the first vaccination and in 37% after the second. Among the participants with baseline HAI titers <1:40, 63% seroconverted. Young age was clearly associated with lower HAI titers at baseline and with higher seroconversion rates, whereas none of the seven patients >60 years of age had a baseline HAI titer <1:40 or seroconverted after vaccination. The vaccine was well tolerated.<h4>Conclusion</h4>The non-adjuvanted pandemic influenza A (H1N1) vaccine was well tolerated and induced a measurable immune response in a sample of HIV-infected individuals.Heimo LaglerKatharina Grabmeier-PfistershammerVeronique Touzeau-RömerSelma TobudicMichael RamharterJudith WenischGuido Andrés GualdoniMonika Redlberger-FritzTheresia Popow-KrauppArmin RiegerHeinz BurgmannPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 5, p e36773 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Heimo Lagler Katharina Grabmeier-Pfistershammer Veronique Touzeau-Römer Selma Tobudic Michael Ramharter Judith Wenisch Guido Andrés Gualdoni Monika Redlberger-Fritz Theresia Popow-Kraupp Armin Rieger Heinz Burgmann Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals. |
| description |
<h4>Background</h4>During the influenza pandemic of 2009/10, the whole-virion, Vero-cell-derived, inactivated, pandemic influenza A (H1N1) vaccine Celvapan® (Baxter) was used in Austria. Celvapan® is adjuvant-free and was the only such vaccine at that time in Europe. The objective of this observational, non-interventional, prospective single-center study was to evaluate the immunogenicity and tolerability of two intramuscular doses of this novel vaccine in HIV-positive individuals.<h4>Methods and findings</h4>A standard hemagglutination inhibition (HAI) assay was used for evaluation of the seroconversion rate and seroprotection against the pandemic H1N1 strain. In addition, H1N1-specific IgG antibodies were measured using a recently developed ELISA and compared with the HAI results. Tolerability of vaccination was evaluated up to one month after the second dose. A total of 79 HIV-infected adults with an indication for H1N1 vaccination were evaluated. At baseline, 55 of the 79 participants had an HAI titer ≥1:40 and two patients showed a positive IgG ELISA. The seroconversion rate was 31% after the first vaccination, increasing to 41% after the second; the corresponding seroprotection rates were 92% and 83% respectively. ELISA IgG levels were positive in 25% after the first vaccination and in 37% after the second. Among the participants with baseline HAI titers <1:40, 63% seroconverted. Young age was clearly associated with lower HAI titers at baseline and with higher seroconversion rates, whereas none of the seven patients >60 years of age had a baseline HAI titer <1:40 or seroconverted after vaccination. The vaccine was well tolerated.<h4>Conclusion</h4>The non-adjuvanted pandemic influenza A (H1N1) vaccine was well tolerated and induced a measurable immune response in a sample of HIV-infected individuals. |
| format |
article |
| author |
Heimo Lagler Katharina Grabmeier-Pfistershammer Veronique Touzeau-Römer Selma Tobudic Michael Ramharter Judith Wenisch Guido Andrés Gualdoni Monika Redlberger-Fritz Theresia Popow-Kraupp Armin Rieger Heinz Burgmann |
| author_facet |
Heimo Lagler Katharina Grabmeier-Pfistershammer Veronique Touzeau-Römer Selma Tobudic Michael Ramharter Judith Wenisch Guido Andrés Gualdoni Monika Redlberger-Fritz Theresia Popow-Kraupp Armin Rieger Heinz Burgmann |
| author_sort |
Heimo Lagler |
| title |
Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals. |
| title_short |
Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals. |
| title_full |
Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals. |
| title_fullStr |
Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals. |
| title_full_unstemmed |
Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals. |
| title_sort |
immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza a (h1n1) vaccine in hiv-infected individuals. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2012 |
| url |
https://doaj.org/article/738ef5870b3140ce8bcd14c42c4134ec |
| work_keys_str_mv |
AT heimolagler immunogenicityandtolerabilityaftertwodosesofnonadjuvantedwholevirionpandemicinfluenzaah1n1vaccineinhivinfectedindividuals AT katharinagrabmeierpfistershammer immunogenicityandtolerabilityaftertwodosesofnonadjuvantedwholevirionpandemicinfluenzaah1n1vaccineinhivinfectedindividuals AT veroniquetouzeauromer immunogenicityandtolerabilityaftertwodosesofnonadjuvantedwholevirionpandemicinfluenzaah1n1vaccineinhivinfectedindividuals AT selmatobudic immunogenicityandtolerabilityaftertwodosesofnonadjuvantedwholevirionpandemicinfluenzaah1n1vaccineinhivinfectedindividuals AT michaelramharter immunogenicityandtolerabilityaftertwodosesofnonadjuvantedwholevirionpandemicinfluenzaah1n1vaccineinhivinfectedindividuals AT judithwenisch immunogenicityandtolerabilityaftertwodosesofnonadjuvantedwholevirionpandemicinfluenzaah1n1vaccineinhivinfectedindividuals AT guidoandresgualdoni immunogenicityandtolerabilityaftertwodosesofnonadjuvantedwholevirionpandemicinfluenzaah1n1vaccineinhivinfectedindividuals AT monikaredlbergerfritz immunogenicityandtolerabilityaftertwodosesofnonadjuvantedwholevirionpandemicinfluenzaah1n1vaccineinhivinfectedindividuals AT theresiapopowkraupp immunogenicityandtolerabilityaftertwodosesofnonadjuvantedwholevirionpandemicinfluenzaah1n1vaccineinhivinfectedindividuals AT arminrieger immunogenicityandtolerabilityaftertwodosesofnonadjuvantedwholevirionpandemicinfluenzaah1n1vaccineinhivinfectedindividuals AT heinzburgmann immunogenicityandtolerabilityaftertwodosesofnonadjuvantedwholevirionpandemicinfluenzaah1n1vaccineinhivinfectedindividuals |
| _version_ |
1718423672136400896 |